Driving Cutting-Edge Science

Geneva is at the forefront of cancer research, driving transformative solutions that improve diagnosis, treatment, and survivorship for service members and their families. With a focus on collaboration, we partner with military treatment facilities, federal laboratories, research institutions, and cross-sector organizations to accelerate discoveries and ensure equitable access to care.

Cancer research is essential within the military context, addressing critical gaps in prevention, diagnosis, treatment, and survivorship that directly impact the health and readiness of military populations.

• • Occupational Exposures: Military service-linked exposures to hazardous materials increase the risk of cancers, such as kidney cancer.
  • Lung Cancer Risks: Approximately 900,000 veterans face heightened risks of lung cancer due to factors like smoking, age, and environmental exposures.
  • Operational Exposures: Agent Orange, ionizing radiation, infectious agents, and traumatic brain injuries (TBIs) further elevate cancer risks in military populations.

The Geneva Advantage

Geneva accelerates military medical research and development (R&D) through strategic collaborations, operational expertise, and innovative solutions that amplify research impact, strengthen national defense, and improve healthcare for service members and the communities they serve.

• • Access to Military Assets and Sites: Collaborations with federal labs and military treatment facilities, including the National Cancer Institute, Uniformed Services University, and Madigan Army Medical Center.
  • Proven Performance: Decades of experience advancing research that bridges military readiness and patient care, with proven expertise in navigating the complexities of military-focused research and funding mechanisms.
  • Strategic Innovation: Pioneering projects in biomarker discovery, immunotherapy, and translational medicine, ensuring rapid progression from research to clinical impact.